Publication of List of Manufacturers Suspended from Licensing for the Manufacture of Therapeutic Goods – 9 April 2025

Overview

The Therapeutic Goods Act 1989 was enacted to ensure that therapeutic goods available in Australia are of an acceptable quality, safety, and efficacy. The Act was introduced to address the need for stringent regulation and control over the manufacture, importation, supply, and advertising of therapeutic goods, including medicines, medical devices, and blood and blood components. The Therapeutic Goods Administration, acting under the authority of the Commonwealth of Australia's Department of Health and Aged Care, administers the Act to safeguard public health by ensuring that therapeutic goods meet necessary standards. The policy objective is to protect the health and safety of the Australian population by maintaining a robust regulatory framework that enforces compliance with quality and safety standards, thereby mitigating risks associated with substandard or unsafe therapeutic goods. This gazette serves to inform the public and relevant stakeholders of current suspensions of manufacturers' licences, ensuring transparency and accountability in the therapeutic goods supply chain.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA) under the Department of Health and Aged Care, governs the regulation of therapeutic goods in Australia. This Act applies to entities and individuals involved in the manufacturing, supply, and advertising of therapeutic goods, including pharmaceuticals, medical devices, and complementary medicines. The legislation encompasses the entire Commonwealth jurisdiction, providing a national standard for the safety, quality, and efficacy of therapeutic goods available in Australia. Notably, the Act can extend its application through subordinate instruments, such as regulations and standards, which provide detailed requirements and procedures for compliance. The gazetted suspension of manufacturing licences, as seen in the recent publication concerning AEGROS LIMITED, EDWARD D CO PTY LTD, and LITTLE GREEN PHARMA LTD, demonstrates the enforcement mechanism under Section 41 of the Act, allowing the Secretary to suspend licences at the request of the manufacturer or on other grounds. These suspensions are specific to the named entities and are subject to the terms outlined in the notice, indicating the precision and targeted approach of the regulatory framework in ensuring compliance and public safety.

Key Provisions

The Therapeutic Goods Act 1989, in particular Section 41(1)(d), provides the authority for the Secretary of the Department of Health and Aged Care, Therapeutic Goods Administration, to suspend a manufacturer's licence. The act enables the Secretary to publish details of any such suspensions by notice in writing. The gazette issued on 9 April 2025 includes details of the suspension of licences held by AEGROS LIMITED, Edward D Co Pty Ltd trading as National Pharma Pack, and Little Green Pharma Ltd. These suspensions, requested by the manufacturers themselves, are in effect from specified dates until corresponding end dates. The obligations under the Therapeutic Goods Act 1989 for manufacturers include maintaining high standards of quality, safety, and efficacy in the production of therapeutic goods. The Act mandates that manufacturers adhere to good manufacturing practices, ensuring that their facilities, processes, and products meet the required standards. Additionally, manufacturers must submit detailed information about their manufacturing processes and products to the Therapeutic Goods Administration for review and approval. Failure to comply with the provisions of the Therapeutic Goods Act 1989 can result in various penalties and consequences. For instance, any manufacturer found to be in breach of the Act may face suspension or revocation of their licence, as seen in the gazette. Such actions are taken to protect public health and safety by preventing substandard or unsafe therapeutic goods from entering the market. The maximum penalties for breaches can include substantial fines, imprisonment, or both, depending on the severity and nature of the breach. Additionally, civil actions may be pursued to seek compensation for any harm caused by non-compliance with the Act.